PT - JOURNAL ARTICLE AU - Maria G Byazrova AU - Sergey V Kulemzin AU - Ekaterina A Astakhova AU - Tatyana N Belovezhets AU - Grigory A Efimov AU - Anton N Chikaev AU - Ilya O Kolotygin AU - Andrey A Gorchakov AU - Alexander V Taranin AU - Alexander V Filatov TI - Memory B cell and humoral responses elicited by Sputnik V in naïve and COVID-19-recovered vaccine recipients AID - 10.1101/2021.10.13.21264894 DP - 2021 Jan 01 TA - medRxiv PG - 2021.10.13.21264894 4099 - http://medrxiv.org/content/early/2021/10/17/2021.10.13.21264894.short 4100 - http://medrxiv.org/content/early/2021/10/17/2021.10.13.21264894.full AB - The development of effective vaccines against SARS-CoV-2 remains a global health priority. Despite extensive use, the effects of Sputnik V on B cell immunity need to be explored in detail. We show that B memory cell (MBC) and antibody responses to Sputnik V were heavily dependent on whether the vaccinee had a history of SARS-CoV-2 infection or not. In vitro stimulated MBCs from previously infected recipients of Sputnik V secreted a significant amount of anti-RBD IgG both on days 28 and 85 from the beginning of vaccination. These antibodies demonstrated robust neutralization of the Wuhan Spike-pseudotyped lentivirus. In the naïve group of vaccinees, the level of anti-RBD IgG secretion was five- to six-fold reduced compared to that of the recovered group, and maximum virus neutralization (Wuhan spike) was achieved only on day 85. Sera from all the recovered and most naïve Sputnik V recipients were neutralizing against the ancestral Wuhan and mutant B.1.351 viruses. Thus, our in-depth analysis of MBC responses in Sputnik V vaccinees complements traditional serological approaches and may provide important outlook into future B cell responses upon re-encounter with the emerging variants of SARS-CoV-2.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Russian Science Foundation (Project 21-15-00331) and the Russian Fund for Basic Research (20-04-60527).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Medical Ethical Committee of National Research Center Institute of Immunology of Federal Medical Biological Agency of Russia gave ethical approval for this work (#12-1, December 29, 2020).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript